Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?. (May 2018)

• Record Type: Journal Article
• Authors: Whelan, Andy; Johnson, Mark I
• Is Part Of: Pain management. Volume 8:Number 3(2018)
• Page Start: 217
• Page End: 229
• Publication Date: 2018-05
• Subjects: analgesia -- end-of-life care -- LSD -- lysergic acid diethylamide -- pain -- psilocin -- psilocybin; Pain -- Treatment -- Periodicals; 616.047205
• DOI: 10.2217/pmt-2017-0068
• Languages: English
• ISSNs: 1758-1869

Abstract

Recently, there has been interest in lysergic acid diethylamide (LSD) and psilocybin for depression, anxiety and fear of death in terminal illness. The aim of this review is to discuss the potential use of LSD and psilocybin for patients with persistent pain. LSD and psilocybin are 5-hydroxytryptamine receptor agonists and may interact with nociceptive and antinociceptive processing. Tentative evidence from a systematic review suggests that LSD (7 studies, 323 participants) and psilocybin (3 studies, 92 participants) may be beneficial for depression and anxiety associated with distress in life-threatening diseases. LSD and psilocybin are generally safe if administered by a healthcare professional, although further investigations are needed to assess their utility for patients with persistent pain, especially associated with terminal illness.